Article

More Genetic Clues Needed to Improve Lung Cancer Treatment

David Spigel, a lung cancer specialist, explains the potential of biomarkers in the search for new treatments.

David Spigel, director of the Lung Cancer Research Program at Sarah Cannon Research Institute in Nashville, answers CURE's questions on how biomarkers will affect lung cancer treatment now and in the future.

Podcast: David Spigel and the future of lung cancer biomarkers

While only a fraction of lung cancer mutations have a treatment that targets them, Spigel expects that in the near future, many more genetic clues will be uncovered. These discoveries will help shape treatment decisions for a wider range of patients.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Picture of Dr. Pouneh Razavi
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Related Content